dipyridamole has been researched along with Dysphagia in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Excerpt | Relevance | Reference |
---|---|---|
"Many stroke survivors have severe dysphagia and are unable to take antithrombotic medications orally." | 2.75 | Pharmacokinetics of extended-release dipyridamole following administration through a gastrostomy tube: an open-label, case-control, two-centre study. ( Batista, LM; Crandell, D; Greer, DM; Lima, FO, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Batista, LM | 1 |
Crandell, D | 1 |
Lima, FO | 1 |
Greer, DM | 1 |
1 trial available for dipyridamole and Dysphagia
Article | Year |
---|---|
Pharmacokinetics of extended-release dipyridamole following administration through a gastrostomy tube: an open-label, case-control, two-centre study.
Topics: Aged; Aggrecans; Case-Control Studies; Cerebral Infarction; Deglutition Disorders; Delayed-Action Pr | 2010 |